What diseases does adagrasib act on?

Adagrasib (Adagrasib) is a prescription medicine used to treat non-small cell lung cancer (NSCLC) in adults who have spread to other parts of the body or cannot be removed with surgery, whose tumors have an abnormal KRAS G12C gene, and who have received at least one prior treatment. Adagrasiib may also be used in combination with the drug cetuximab to treat colon or rectal cancer (CRC) that has spread to other parts of the body or cannot be removed with surgery and the tumor has an abnormal KRAS G12C gene. and people who have previously received certain chemotherapy drugs.

Adagrasiib is a targeted therapy that inhibits tumor growth in patients with KRAS G12C-mutated non-small cell lung cancer or colorectal cancer by inhibitingKRAS G12C. Adagrasiib tablets are taken by mouth twice daily with or without food.

Warnings and precautions related to adagrasib include gastrointestinal adverse effects, QTc interval prolongation, hepatotoxicity, and interstitial lung disease/pneumonitis.

The most common adverse reactions of adagrasib include diarrhea, nausea, fatigue, vomiting, musculoskeletal pain, hepatotoxicity, renal impairment, dyspnea, edema, decreased appetite, cough, pneumonia, dizziness, constipation, abdominal pain andQTc interval prolongation. The most common laboratory abnormalities include lymphopenia, increased aspartate aminotransferase, decreased sodium, decreased hemoglobin, increased creatinine, decreased albumin, increased alanine aminotransferase, increased lipase, decreased platelets, decreased magnesium, and decreased potassium.

Overall, adagrasib has attracted widespread attention in the field of cancer treatment due to its targeting and therapeutic effects. It not only brings new treatment opportunities to patients with non-small cell lung cancer, but also shows broad application prospects in the treatment of colon or rectal cancer.